SADDLE RIVER, N.J., July 30 /PRNewswire-FirstCall/ -- PDI, Inc. (Nasdaq: PDII), a leading provider of sales and marketing support to U.S. pharmaceutical companies, announced today that current PDI director Gerald P. Belle has been appointed to the newly-established position of lead independent director.
Mr. Belle has been a director of the Company since April 2008. He is also a member of the Audit Committee.
"Jerry has served as an invaluable board member during his tenure with PDI," stated John P. Dugan, Chairman of the Board of PDI, Inc. "In his expanded role, we believe Jerry's experience, knowledge and leadership skills will further enhance the Company's corporate governance structure. We look forward to his continuing contributions."
"I am delighted to accept this new appointment as lead director of PDI, especially as the Company continues to expand its strong presence in the industry and the value proposition it brings to its customers in an ever-changing environment. As such, I look forward to working with PDI management and my fellow board members who remain committed to helping achieve the Company's growth goals while maintaining the highest standards of corporate governance," stated Mr. Belle.
From 2004 until his retirement in November 2007, Mr. Belle served as Executive Chairman of Merial Ltd., a global animal health company that is a joint venture between Sanofi-aventis and Merck & Co. Prior to that, Mr. Belle served as President and Chief Executive Officer, North America Pharmaceuticals for Aventis, Inc. He retired after 35 years of service at Aventis and its predecessor companies. Mr. Belle is Chairman of the Board of Myriad Pharmaceuticals, Inc., a publicly traded biopharmaceutical company and also a member of the board of directors of Myriad Genetics, Inc.,
|SOURCE PDI, Inc.|
Copyright©2009 PR Newswire.
All rights reserved